CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 478 enrolled
Drug / intervention
Bimekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03412747
NCT03412747Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

UCB Biopharma SRL·interventional·Posted Jan 26, 2018·Updated Apr 15, 2026

In Brief

A Phase 3 clinical trial evaluating Bimekizumab, Adalimumab, and 1 other intervention for Chronic Plaque Psoriasis and Moderate to Severe Plaque Psoriasis. Completed, enrolled 478 participants across 77 sites in 9 countries.

Detailed Summary

This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
CountriesAustralia, Canada, Germany, Hungary, Poland, Russia, South Korea, Taiwan, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 26, 2018
Enrollment StartJan 26, 2018
Primary CompletionFeb 7, 2019
Study CompletionFeb 26, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.4 years ago

Interventions

Bimekizumabdrug

Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.

Adalimumabdrug

Adalimumab will be administered according to the labeling recommendations.

Placeboother

Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).